FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have Symptomatic Plexiform Neurofibromas Not Amenable to Complete Resection By Ogkologos - March 20, 2025 750 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ReNeu study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin April 30, 2025 ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to... September 18, 2025 EMA Recommends Granting a Marketing Authorisation for Inavolisib June 26, 2025 Expanding the horizons of the life science economy May 3, 2022 Load more HOT NEWS Remote Monitoring of Patients Treated with Oral Anticancer Drugs Improves Patient... New Blood Test Can Screen For Over 50 Cancers FDA Approves Acalabrutinib with Bendamustine and Rituximab for Previously Untreated Mantle... FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer
